<DOC>
	<DOCNO>NCT01900327</DOCNO>
	<brief_summary>Sequential Neoadjuvant Chemoradiotherapy ( CRT ) Followed Curative Surgery vs. Primary Surgery Alone Resectable , Non-metastasized Pancreatic Adenocarcinoma</brief_summary>
	<brief_title>Neoadjuvant Treatment Resectable Pancreatic Cancer</brief_title>
	<detailed_description>Median overall-survival ( OS ) surgery curative intent non-metastasized pancreas cancer range study condition 17.9 month 23.6 month . Tumor recurrence occur locally , distant site ( liver , peritoneum , lung ) , . Observational autopsy series report local recurrence rate 87 % even potentially `` curative '' R0 resection . To achieve good local control , neoadjuvant chemo-radiation therapy ( CRT ) suggest preoperative tumour downsizing , elevate likelihood curative , margin-negative R0 resection increase OS rate . However , control , randomize trial address impact neoadjuvant CRT survival exist . The underlying hypothesis randomize , two-armed , open-label , multicenter , phase III trial neoadjuvant CRT increase three-year overall survival 12 % ( 30 % 42 % ) compare patient undergo upfront surgery resectable pancreatic cancer . Overall , 410 patient ( n=205 study arm ) enrol trial , take regard expect drop rate 7 % allocate either receive neoadjuvant CRT prior surgery undergo surgery alone . Circumferential resection margin status , i.e . R0 R1 rate , respectively , surgical resectability rate , local distant disease-free global survival , first site tumor recurrence constitute essential endpoint trial .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologyproven adenocarcinoma pancreatic head/uncinate process tumor size great 2 cm ( ≥cT2 ) and/or close contact superior mesenteric vessel ( ≤3 mm preoperative staging ) . No evidence metastasis distant organ ( liver , peritoneum , lung , others ) . For determination resectability , multidetector CT ( MDCT ) least 16 row apply oral intravenous contrast medium perform . MDCTbased imaging focus upper abdomen native , arterial , parenchyma phase , parenchyma phase include pelvis . Imaging criterion derive recent consensus definition Society Surgical Oncology , American Society Clinical Oncology American HepatoPancreaticoBiliary Association [ 1 ] apply preoperative assessment local resectability . Potential Resectability : visualizable fat plane around celiac superior mesenteric artery , patent superior mesenteric/portal vein ( SMV/PV ) . Borderline Resectability : substantial superior mesenteric/portal vein impingement , tumor abutment SMA &lt; 180° , GDA encasement origin hepatic artery , colonic/mesenteric root invasion . Karnofsky performance status ≥ 80 % Serum creatinine level ≤ 3.0 mg/dl Serum total bilirubin level ≤ 3.0 mg/dl absence biliary obstruction ( In event biliary obstruction , patient allocate CRT group must undergo interventional endoscopy percutaneous drainage biliary decompression . Postinterventionally , bilirubin level ≤ 3.0 mg/dl patient subject CRT . In control patient undergo upfront surgery , serum total bilirubin level ≤ 10.0 mg/dl tolerate , unless clinical laboratory sign severe cholangitis take place . Patients serum total bilirubin level &gt; 10.0 mg/dl undergo preoperative biliary decompression , preferentially interventional endoscopy ) White blood cell count ≥ 3.5 x 109/ml , platelet count ≥ 100 x 109/ml Ability understand willingness consent formal requirement study participation Written inform consent Age ≤ 18 year Neuroendocrine , acinar cancer Cancers pancreatic body tail , i.e . lesion leave SMV Recurrent disease Infiltration extrapancreatic organ ( except duodenum transverse colon ) Persistent cholestasis/cholangitis despite adequate biliary stenting Gastric outlet obstruction , especially event endoscopically evidence tumor invasion gastroduodenal mucosa . Tumor specific pretreatment History gastrointestinal perforation , e.g . perforate colonic diverticulitis , abdominal abscess intestinal fistula within 6 month prior potential study participation Radiographic evidence severe portal hypertension/cavernomatous transformation may , discretion participate investigator , hamper surgery Other concurrent malignancy except basal cell cancer skin insitu cervical cancer Premalignant hematologic disorder , e.g . myelodysplastic syndrome Severe organ dysfunction ( e.g . Liver cirrhosis ≥ Child B ; Cardiopulmonal disease ( NYHA ≥III , arrhythmia Lown III/IV , global respiratory insufficiency ) ; Ascites ; Acute pancreatitis ; bleed diathesis , coagulopathy , need fulldose anticoagulation INR &gt; 1.5 ; severe disease might prevent completion treatment regimen ) Chronic infectious disease , especially immune deficiency syndrome , e.g . HIV infection , active tuberculosis within 12 month prior potential study participation History severe neurologic disorder , e.g . cerebrovascular ischemia History prior deep venous thrombosis pulmonary embolism Pregnant nursing woman ineligible patient reproductive potential must agree use effective contraceptive method participation trial 6 month follow trial Serious medical , psychological , familial , sociological geographical condition circumstance potentially hamper compliance study protocol followup Participation clinical trial last 6 month allocation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>surgery</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>neoadjuvant treatment</keyword>
	<keyword>overall survival</keyword>
</DOC>